A cervical cancer diagnosis can make every medical term on your report feel urgent. Understanding cervical cancer stages gives you a clearer way to discuss your diagnosis, scans, and treatment plan with your doctor.
The stage describes where the cancer is found, how large it is, and whether it has reached nearby tissues, lymph nodes, or distant organs. It does not predict your future on its own.
Quick Answer
Doctors classify cervical cancer using FIGO staging. Stage I is confined to the cervix, while Stage IV has spread to distant organs.
Your final stage may change after your oncologist reviews clinical findings, including examination results, biopsy, pathology, MRI, CT, PET scan, and lymph node findings.
A higher stage does not mean treatment choices are gone. Cancer involving nearby areas, such as the pelvic wall, may require a different combination of treatments.
Key Takeaways
- Stage I cancer is limited to the cervix. Stage IA is the earliest form and may be described as microinvasive disease.
- Doctors assess tumour size and depth of stromal invasion, alongside scans and pathology findings, to assign a stage.
- Stage IIIC means cancer has reached pelvic or para-aortic lymph nodes.
- Stage IVB indicates metastasis to distant organs, such as the lungs, liver, or bones.
- Your treatment plan depends on more than the stage. Biopsy results, biomarkers, medical history, fertility wishes, hospital resources, and your oncologist’s assessment also matter.
How Cervical Cancer Stages Are Decided
Staging begins after a cancer diagnosis has been confirmed through a biopsy. Your doctor reviews the clinical findings from examining the cervix and nearby pelvic structures. However, modern staging doesn’t rely on examination alone.
Diagnostic imaging then adds information to the examination. A pelvic MRI scan can measure tumor size and show whether the cancer has reached nearby tissue. CT scans and PET scans can help identify enlarged or active lymph nodes and possible spread elsewhere.
The National Cancer Institute’s cervical cancer stage guide outlines the central idea: Stage I stays in the cervix, while later stages describe further spread. FIGO staging allows doctors to incorporate imaging and pathology findings. Pathology review can clarify stromal invasion, but the stage may be confirmed or updated only after the full record is reviewed.
The 2018 revision remains the staging framework used in current clinical references. It added more detail for early tumours and formally included imaging and pathology information. A 2024 review of FIGO staging changes explains why this matters for patients whose scans or surgical pathology provide information that a pelvic examination cannot show.
Stages I to IV: What Each Stage Means
The table below gives a plain-language view of the main stages. Reports may include additional letters and numbers because FIGO staging includes substages.
| Stage | What it generally means |
|---|---|
| Stage I | Cancer is confined to the cervix. |
| Stage II | Cancer has grown beyond the cervix and uterus, but has not reached the pelvic wall or lower third of the vagina. |
| Stage III | Cancer has reached the lower third of the vagina or the pelvic wall, caused kidney blockage, or includes regional nodal involvement. |
| Stage IV | Cancer has spread outside the pelvis or to other parts of the body. |
The stage helps your oncology team discuss treatment, but it is only one part of the picture.
Stage I: Cancer limited to the cervix
Stage IA describes microinvasive disease that cannot be assessed by sight alone and requires microscopic examination. It is defined by stromal invasion, which measures how deeply cells enter the supportive cervical stroma.
- Stage IA1 means stromal invasion is 3 mm or less in depth.
- Stage IA2 means stromal invasion is more than 3 mm but no more than 5 mm.
The distinction can affect decisions about fertility-sparing surgery, nodal assessment, and the amount of tissue removed. Horizontal spread no longer separates IA1 from IA2. Depth of stromal invasion is the key measurement.
Stage IB means the cancer has invaded more than 5 mm into the cervical stroma, but remains confined to the cervix. Doctors use tumor size, measured by the greatest diameter, to divide it further:
- IB1 is up to 2 cm.
- IB2 is more than 2 cm up to 4 cm.
- IB3 is more than 4 cm.
For carefully selected early cases, surgery may include conisation, trachelectomy, or hysterectomy. The right option depends on nodal findings, margin status, fertility plans, and the full pathology report review.
Stage II: Beyond the cervix, but still within the pelvic region
Stage II cancer has extended beyond the cervix and its immediate structures, but remains within the pelvic region. It has not reached the pelvic wall.
Stage IIA involves the upper two-thirds of the vagina without parametrial involvement. IIA1 tumours are 4 cm or smaller, while IIA2 tumours are larger than 4 cm.
Stage IIB means the cancer has entered the parametrium, indicating parametrial involvement, but remains within the central pelvic region. At this point, doctors often consider combined radiation therapy and chemotherapy rather than surgery alone. Brachytherapy, which places radiation close to the tumour site, is often an important part of this approach for suitable patients.
Stage III: Pelvic extension or nodal involvement
Stage III includes several different situations. Stage IIIA means the cancer has reached the lower third of the vagina but not the outer boundary of the pelvic region. Stage IIIB means it has reached the pelvic wall or caused hydronephrosis, a kidney swelling caused by urinary blockage, or a non-functioning kidney.
Stage IIIC is different because it reflects involvement of lymph nodes, regardless of the primary tumor’s size. This was a major update in FIGO staging.
- Stage IIIC1 means cancer has spread to pelvic nodes.
- Stage IIIC2 means cancer has reached para-aortic lymph nodes, which sit higher in the abdomen near the aorta.
Your report may state IIIC1r or IIIC2r when radiology supports the finding. A “p” may appear when pathology confirms it. The staging revision review explains why nodal disease now has its own category.
Stage IV: Advanced spread
Stage IVA means the cancer has spread to nearby pelvic organs, usually involving the bladder or rectum. Doctors need biopsy proof of lining involvement in the affected organ. Swelling seen on a scan alone does not confirm Stage IVA.
Stage IVB is defined by metastasis beyond the pelvic and para-aortic regions. This can include spread to the lungs, liver, bones, or distant organs.
Advanced cancer treatment may involve systemic medicines, radiation for symptom control or local disease, and supportive care. Your specialist may discuss immunotherapy, targeted therapy, or a clinical trial when appropriate. Suitability depends on biopsy findings, biomarkers, prior treatment, overall health, and treatment availability.
Why Imaging and Pathology Can Change the Stage
A cervical screening result can identify people who need further assessment, but it cannot diagnose invasive cancer. HPV testing and Pap tests identify risk or cell changes. Colposcopy allows a doctor to examine the cervix more closely. A biopsy confirms whether cancer is present.
For early disease, a LLETZ procedure, cone procedure, or larger excision can provide precise measurements. The pathologist checks tumour type, depth of stromal invasion, surgical margins, and lymphovascular space invasion. Lymphovascular space invasion does not set the FIGO stage by itself. The depth of stromal invasion can influence treatment planning.
Diagnostic imaging complements pathology when doctors assess disease extent. MRI is especially useful for assessing local tumour size in the pelvis, parametrial involvement, and nearby organs. CT and PET-CT scans help assess lymph nodes and distant organs. Doctors may also order blood tests to check kidney and liver function before treatment.
The 2018 update was important because it formally allowed radiological and pathological evidence in staging. The multidisciplinary explanation of revised FIGO staging describes how scans and pathology can provide a more complete measure of disease extent.
Two common histological types are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma starts in thin cells on the outer surface of the cervix. Adenocarcinoma starts in glandular cells within the cervical canal. Both use the same staging system, but their appearance, tissue sampling approach, and treatment discussion can differ.
Biomarker testing and selected genetic testing for cancer may become more relevant in recurrent or metastatic disease. They do not replace staging, but they can affect which cancer treatment options may be considered.
Treatment Choices at Different Stages
There is no single treatment plan for everyone with the same stage. FIGO staging guides decisions, but it does not determine treatment by itself. Your cancer specialist will consider tumour type, scans, biopsy findings, pathology, lymph nodes, biomarkers, and relevant genetic testing. Your health, fertility goals, access to care, and preferences also matter.
Early-stage disease may be treated with surgery. Histology also matters, since squamous cell carcinoma and adenocarcinoma can influence treatment discussions. For some people with very early cancer who hope to have children, a cone biopsy or radical trachelectomy may be discussed. Others may need a hysterectomy, which removes the uterus, with or without assessment of nearby nodes.
For many Stage IB3, Stage II, and Stage III cancers, doctors may recommend external-beam radiation therapy with chemotherapy, followed by brachytherapy. This combined approach can make cancer cells more sensitive to radiation. Your team will explain expected benefits, side effects, and practical arrangements before treatment begins.
For Stage IVB or recurrent cervical cancer, the presence of metastasis may change treatment goals and options. Systemic treatment may include drug treatment, immunotherapy, or targeted therapy when testing supports its use. Radiotherapy can also help treat particular areas that cause symptoms.
A stage-based cervical cancer treatment reference shows why treatment recommendations change as the disease extends beyond the cervix. Your care should be guided by an oncology consultation, not by a stage label alone.
Survival Statistics Need Careful Context
You may find five-year survival rate figures while searching for cervical cancer stages. These figures describe large groups treated in earlier years. They cannot predict how a specific treatment will work for you.
Published data may group disease as localised, regional, or distant rather than using exact FIGO stages. Stage I is usually localised. Stages II and III often fall within regional disease, although outlook varies widely based on tumour size, lymph node status, treatment response, and other health factors. Stage IVB usually falls within distant disease, including cancer that has reached distant organs.
Your oncologist can explain what your stage means in your own situation. Ask which details in your report affect outlook, including recurrence risk and future monitoring. A published survival rate should not be applied directly to one patient.
Symptoms, Screening, and Follow-Up
Early cervical cancer may cause no symptoms. When symptoms occur, they can include unusual vaginal bleeding, bleeding after sex, bleeding after menopause, unusual discharge, pelvic pain, or pain during sex. These symptoms can have non-cancer causes, but they still need medical review.
Do not wait for symptoms before attending cervical cancer screening. Screening can detect human papillomavirus (HPV) infection or abnormal cells before invasive cancer develops. If you have persistent symptoms, see a doctor even if a previous screening test was normal.
After treatment, follow-up visits help your team check recovery, manage side effects, and monitor for signs of recurrence. Keep a copy of your medical reports, scan results, pathology findings, and treatment summaries.
Questions to Ask During Your Oncology Consultation
Bring a family member or write down your questions before the appointment. You may want to ask:
- What is my exact FIGO stage, and can another specialist review my pathology report and scans?
- What type of cervical cancer do I have, and are there pathology features that affect treatment?
- Has the cancer spread to pelvic or para-aortic lymph nodes?
- Is surgery appropriate for me, and could treatment affect fertility or menopause?
- Why is chemotherapy, radiotherapy, brachytherapy, or another approach recommended?
- Do I need biomarker testing before starting treatment?
- Which side effects require urgent medical attention?
- Can I receive a written cancer treatment quotation and an estimate of follow-up costs?
Considering Cost, Hospital Choice, and a Second Opinion
Cancer treatment costs can vary because care may involve surgery, scans, pathology, radiotherapy planning, brachytherapy sessions, medicines, hospital stays, and follow-up appointments. Ask the cancer hospital for an itemised estimate. If you are comparing public and private options, ask about referral requirements and cancer treatment waiting times.
A cancer second opinion can be reasonable when the diagnosis is uncommon, the stage is unclear, fertility preservation matters, or you are choosing between surgery and chemoradiation. Another specialist can review your medical report, pathology slides, scans, and recommended care.
If you are comparing cancer hospitals or considering overseas cancer treatment, request a complete review of your medical records first. Coordination support can help organise records and explain practical choices. It cannot replace an oncologist’s medical assessment or guarantee a treatment outcome.
Final Thoughts
The most useful question is not only “What stage is it?” Ask how the stage, scan findings, pathology, and your personal priorities shape your treatment choices.
Clear records and direct conversations with your oncology team can make the next decision more manageable. Cervical cancer stages provide a shared language, while your treatment plan should remain personalised to you.
Frequently Asked Questions
Is Stage 0 cervical cancer?
You may still see “Stage 0” in older materials. The current FIGO staging system does not classify carcinoma in situ as invasive Stage 0. It generally refers to pre-invasive changes, such as carcinoma in situ, which need medical management but haven’t invaded the cervical stroma.
What is the difference between Stage IA1 and IA2?
Both are microscopic cancers found through microscopic examination of tissue. IA1 has stromal invasion of 3 mm or less, while IA2 is deeper than 3 mm but no more than 5 mm. This difference may affect discussions about nodal assessment and fertility-sparing treatment.
Does Stage IIIC always mean the cancer is in a distant organ?
No. Stage IIIC means cancer has pelvic nodal involvement or affects para-aortic lymph nodes. It does not automatically mean distant metastasis. Stage IVB describes spread to distant organs or distant nodal sites.
Can an MRI or PET scan change my stage?
Yes. MRI, CT, and PET-CT scans, together with pathology findings, can show tumour extent or nodal involvement that wasn’t clear during examination. Your doctor may update the stage after reviewing these results.
Can I seek a second opinion before treatment?
Yes. You can ask another cancer specialist to review your biopsy, pathology report, scans, and proposed treatment. Try to arrange this promptly, so it does not create an unnecessary delay in care.
Medical disclaimer: This content is for general information only. It may not be fully verified, current, or applicable to every patient, and it must not be treated as medical advice, diagnosis, or treatment recommendation. Consult your own doctor, oncologist, or qualified healthcare professional before making any medical decision. SureLah does not take responsibility for medical decisions, treatment outcomes, doctor recommendations, hospital decisions, or patient actions based on this article.
